LLTP Stock News Lightlake Therapeutics (LLTP) 0.0520 07/26/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lightlake Therapeutics (LLTP) 0.0520 $LLTP

Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse
PR Newswire - Wed Jul 23, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has filed an investigational new drug application ("IND" with respect to its naloxone-based opioid overdose reversal nasal spray. Lightlake also announced today that it has received an additional commitment from the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to fund a second study with respect to Lightlake's nasal spray. Lightlake, in collaboration with NIDA, previously commenced a clinical trial with respect to its nasal spray in September 2013.

Lightlake Therapeutics Inc. Signs Agreement With Commercial Contract Manufacturer For Its Opioid Overdose Reversal Treatment
PR Newswire - Wed Jul 09, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTCQB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed an agreement with a commercial contract manufacturer to commence production of its naloxone-based opioid overdose reversal treatment. Lightlake expects that this manufacturer will be able to provide sufficient manufacturing capacity at cGMP production facilities to enable commercialization of its treatment on a global scale.

Bulimia Nervosa Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/t543w6/bulimia_nervosa) has announced the addition of the "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" report to their offering. "Bulimia Nervosa Global Clinical Trials Review, H1, 2014" provides data on the Bulimia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bulimia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bulimia Nervosa. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Lightlake Therapeutics Inc. - Interapy PLC Clinical Trial Overview of Top Institutes / Government - New York State Psychiatric Institute - The University of North Carolina - National Institute of Mental Health - Kaiser Permanente - The National Institute of Diabetes and Digestive and Kidney Diseases - Lindner Center of HOPE - Neuropsychiatric Research Institute - Ministry of Education and Research, Germany - Medical University of Vienna - University of Michigan For more information visit http://www.researchandmarkets.com/research/t5...ia_nervosa

Lightlake Therapeutics Inc. To Present At The Third Annual Marcum MicroCap Conference
PR Newswire - Thu May 22, 7:30AM CDT
Lightlake Therapeutics Inc. ("Lightlake" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be a featured presenter at the 3rd Annual Marcum MicroCap Conference on Thursday, May 29, 2014 in New York City at the Grand Hyatt Hotel.

Lightlake Therapeutics Inc. Chief Executive Officer Letter to Shareholders
PR Newswire - Fri Dec 20, 8:00AM CST
Lightlake Therapeutics Inc. ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, today issued a letter by Chief Executive Officer Dr. Roger Crystal updating shareholders on the Company's progress in 2013.

OTC Signal Daily Stock Watch - Lightlake Therapeutics Inc., (OTCQB: LLTP)
WorldStockWire - Tue Sep 03, 8:00PM CDT
OTC Signal tracks stocks daily and is pleased to offer its stock alerts. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Signal at the following: http://www.otcsignal.com

Lightlake Therapeutics Announces Partnership with National Institute on Drug Abuse (NIDA) to Treat Opioid Overdose
PR Newswire - Wed Aug 21, 7:30AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" . This fall, NIDA will sponsor a two-week clinical study designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

Lightlake Therapeutics Retains KCSA Strategic Communications as Corporate Communications Advisors
PR Newswire - Mon Aug 05, 8:00AM CDT
Lightlake Therapeutics Inc., ("Lightlake" or the "Company" (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has retained KCSA Strategic Communications ("KCSA" , a leading New York-based communications firm, to direct the Company's investor and public relations programs.

Lightlake Therapeutics Inc. to Present at 4th Annual OneMedForumNY 2013
Business Wire - Tue Jun 18, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it will be participating in the 4th Annual OneMedForum New York taking place June 26th and June 27th, 2013 at The Metropolitan Club in New York City. Dr. Roger Crystal, Chief Executive Officer of Lightlake, is scheduled to present an update on the Company's corporate and clinical developments on Thursday, June 27th at 12:20 p.m. EDT.

Lightlake Therapeutics' Binge Eating Disorder Treatment Phase II Trial Results Presented At APA 2013 Annual Meeting
Business Wire - Thu May 23, 7:30AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder ("BED" were presented at the American Psychiatric Association ("APA" Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.

Lightlake Therapeutics Inc. to Develop Opioid Drug Treatment in Collaboration with the National Institute on Drug Abuse (NIDA)
Business Wire - Wed Apr 24, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that it has signed a collaboration agreement with the Division of Pharmacotherapies and Medical Consequences of Drug Abuse ("DPMCDA" of the National Institute on Drug Abuse ("NIDA" , part of the National Institutes of Health ("NIH" , to co-develop a treatment for opioid addiction that utilizes the Company's innovative proprietary technology.

Lightlake Therapeutics Inc. Provides Guidance on Company Operations
Business Wire - Thu Apr 04, 8:00AM CDT
Lightlake Therapeutics Inc. (OTCBB: LLTP) (the "Company", "We" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today the clinical progress and corporate developments the Company has achieved during the last six months, and provided insights on its plans to develop opioid drug addiction treatments.

Lightlake Therapeutics Announces Phase II Clinical Trial Results of Treatment for Binge Eating Disorder Accepted at the American Psychiatric Association Annual Meeting
Business Wire - Wed Mar 27, 5:30AM CDT
Lightlake Therapeutics Inc. ( OTCBB: LLTP) (the "Company" or "Lightlake" , an early stage biopharmaceutical company developing addiction treatments, announced today that a scientific abstract based on results of the Company's Phase II clinical trial of its opioid antagonist nasal spray treatment for patients with Binge Eating Disorder (BED) has been accepted for presentation at the American Psychiatric Association Annual Meeting taking place in San Francisco, California, May 18-22, 2013.

Addiction - Pipeline Review: Latest updates and review of key players
M2 - Wed Jan 09, 4:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/vd2xs3/addiction) has announced the addition of Global Markets Direct's new report "Addiction - Pipeline Review, H2 2012" to their offering. This report provides information on the therapeutic development for Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Addiction. Addiction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Addiction. - A review of the Addiction products under development by companies and universities/research institutes based on information derived from com
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 125

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 80

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Zettia R. Barnes: Charting a Path in Home Healthcare

Updated Category News Views 146

The Lifeline of Home Healthcare in DeSoto You know, it ain't every day that someone like Zettia R. Barnes steps up in the realm of home healthcare and makes a mark that genuinely sticks. From rubbing shoulders with patients to steering a whole dang organization like Angels of Hands Home Health Agency Corp., she's got her hands full—and frankly, it’s folks like her who...

Continue Reading
InPHRED's Award Brings 1310 nm VCSELs Into Focus at IEEE

Updated Category News Views 23

A stubborn mirror problem just put InPHRED on the photonics map. InPHRED, founded in 2023, took the Best Technology award at the inaugural 2026 IEEE Photonics Conference Start-Up Competition, selected from seven finalists. That is a meaningful industry pat on the back, particularly because the company is aiming at a real engineering headache rather than waving around...

Continue Reading
The Melt Grabs Top Spot in Burger Ratings War

Updated Category News Views 122

Burger Battle: The Melt Claims Victory When you're in the cutthroat world of fast-casual dining, grabbing the top spot on any list is no small potatoes. The Melt did just that, snatching the title of America’s Highest-Rated Burger Spot. Based on an in-depth analysis of Google and Yelp reviews, folks have spoken, loud and clear, over the past two years. It's a world...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 130

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 65

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 142

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
SKE Capitalizes on Halloween Events in London

Updated Category News Views 162

SKE's Bold Step into London's Halloween Vibe Hah! Who would've thought that vaping and Halloween could be a match made in heaven? This year, SKE threw its hat into the ring and wrestled for attention in London’s bustling Halloween music scene. Imagine an entire warehouse pulsing not just with beat-heavy electronic music, but the energy of vaping enthusiasts courtesy of...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 154

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading

Top 5 Most Recently Viewed Articles

ANI Pharmaceuticals Raises 2025 Guidance Driven by Growth

Updated Category News Views 505

Strong Financial Performance for ANI Pharmaceuticals ANI Pharmaceuticals Inc has recently shared impressive financial results that paint a bright picture for the company's future. The company reported a remarkable adjusted earnings per share (EPS) of $1.63 for the fourth quarter, which represents a noticeable increase from $1.00 recorded in the previous year. This result...

Continue Reading
Growth of Fast Casual Restaurants in the U.S.: Market Insights

Updated Category News Views 374

Overview of the Fast Casual Restaurants Market Growth The fast casual restaurants market in the United States is on a remarkable growth trajectory. According to recent reports, the market is anticipated to expand significantly, with an estimated growth of USD 65.2 billion projected between 2024 and 2028. This surge underscores the increasing popularity of dining options...

Continue Reading
TAL Education Group Prepares to Release Q3 Financial Insights

Updated Category News Views 244

TAL Education Group Announces Financial Reporting Plans TAL Education Group, also known simply as TAL, is gearing up for an important announcement regarding its financial performance. The company, a leader in smart learning solutions in China, is set to release its financial results for the third quarter of the fiscal year 2026. This quarter concluded on November 30,...

Continue Reading
Inspire Medical Systems Faces Securities Fraud Claims Over Softwares

Updated Category News Views 130

Inspire Medical Systems' Class Action Lawsuit Overview Investors have recently become aware of a troubling securities class action lawsuit involving Inspire Medical Systems, Inc. (NYSE: INSP). The law firm Hagens Berman has put out a call for investors who might have suffered significant losses during a specific period to come forward. This call is particularly relevant...

Continue Reading
Scholz Advocates Confidence for German Automakers Amidst China

Updated Category News Views 68

German Automakers Should Embrace Competition, Says Scholz In a recent address, Chancellor Olaf Scholz expressed a confident stance regarding the compatibility of German automakers amidst rising competition from China. Speaking at the inauguration of Mercedes-Benz's first battery recycling plant, Scholz outlined a forward-thinking perspective on Germany's industrial...

Continue Reading